Inna Sekirov
 | This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (November 2022) |
Inna Sekirov is a medical microbiologist and a physician scientist.[1] Sekirov is the Program Head for TB/Mycobacteriology at the British Columbia Centre for Disease Control, and a Clinical Assistant Professor of Pathology and Laboratory Medicine at the University of British Columbia[2] in Vancouver, British Columbia, Canada. Sekirov obtained her PhD, MD, and FRCPC at University of British Columbia, carrying out her PhD work at the Brett Finlay lab. Her research focuses on the public health-related aspects of medical microbiology, clinical applications of microbial genomics and TB/mycobacteriology diagnostic methods.[1]
She has also led COVID-19 research projects on ACEII,[3] antibody responses,[4] and seroprevalence using dried blood spots.[5]
References[edit]
- ^ a b "Inna Sekirov". bccdc.ca. Retrieved 2021-10-21.
- ^ "Inna Sekirov". Pathology. Retrieved 2021-10-21.
- ^ "Prognostication of ACE II Receptor (PACEiiR) | COVID-19 Research". covid19.research.ubc.ca. Retrieved 2021-10-21.
- ^ "Characterizing Antibody Response to Emerging COVID-19 Virus (CARE COVID-19) | COVID-19 Research". covid19.research.ubc.ca. Retrieved 2021-10-21.
- ^ "Accelerating SARS-CoV-2 SEroprevalence SurveyS Through Dried Blood Spots (ASSESS-DBS) | COVID-19 Research". covid19.research.ubc.ca. Retrieved 2021-10-21.
 | This article needs additional or more specific categories. (September 2021) |
 | This article about a biologist is a stub. You can help Wikipedia by expanding it. |